Pharmsynthez PJSC Secures RUB 800m With LDA Capital
24.6.2021 08:00:00 EEST | Business Wire | Press release
Innovative Russian pharmaceutical developer, Pharmsynthez PJSC (MOEX:LIFE), and global alternative investment group, LDA Capital, enter into a Put Option Agreement for 800 million rubles to help finance the development of Pharmsynthez’s pioneering projects over the next 36 months, including those aimed at combating COVID-19.
Both Pharmsynthez and LDA view this capital allocation not only as an investment into the Company but also as a starting point for a long-term strategic partnership to advance Pharmsynthez’s promising projects in the field of innovative pharmaceutical technologies and development of the latest treatments for complex diseases.
LDA Capital’s investments will accelerate Pharmsynthez PJSC projects in all aspects. The Company’s business plan until 2025 allows for the introduction of several highly profitable original drugs (Epolong® and other finished dosage forms) to the domestic market, an increase in the production of active pharmaceutical ingredients, and the launch of the new drugs, such as vaccines that solve various purposes, including: treatment of multiple sclerosis (Xemys®), prevention of hepatitis B (Sci-B-Vac®), COVID-19 and a number of other diseases. In addition, the Company is preparing to bring to market and then localize the production of several generic drugs for the treatment of orphan and oncological diseases, as well as to launch the production of monoclonal antibodies drugs and dry cell culture media for the pharmaceutical industry, becoming a leader in the EAEU market.
Efim Prilezhaev, General Director of Pharmsynthez PJSC, commented: “We are pleased that our partnership with LDA Capital as one of the most successful progressive investors in an environment where interest in pharmaceutical technologies is at an all-time high. Nowadays, the growing demand for innovative developments in the field of biotechnology, the growing risks of pandemics and infectious diseases provide significant growth opportunities for players in this difficult market. We are confident that our partnership with LDA will help deliver outstanding results for the benefit of society.”
Warren Baker, the Managing Partner of LDA Capital, stated: “On the back of secular growth trends in cell culture-based vaccines and monoclonal antibodies (mAb), LDA is enthused to partner with one of the leading Russian pharmaceutical manufacturers. We are excited by Pharmsynthez’s scientific potential and look forward to our continuous cooperation as we remain steadfast on our commitment to providing alternative capital solutions to innovative companies in the global healthcare sector.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005990/en/
Contact information
Robert Baker
LDA Capital
323-471-4325
rbaker@ldacap.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release
Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release
RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom